Macular edema is a vision-limiting complication to BRVO which is effectively treated with intravitreal injections of VEGF inhibitors including bevacizumab, ranibizumab, and aflibercept [4, 6–9]. This evidence concerns the gene VEGFA and macular retinal edema.